Irinotecan Accord

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as a sterile powder for reconstitution for intravenous use. It treats metastatic colorectal cancer and small cell lung cancer in adult patients.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecan is a topoisomerase I inhibitor used in the treatment of colorectal and certain lung cancers.

Metastatic colorectal cancer: used in combination regimens to inhibit tumor growth and improve response rates. Small cell lung cancer: employed as part of multi‑agent chemotherapy to achieve disease control. Adjuvant colon cancer therapy: administered after surgery to reduce recurrence risk in selected patients.

Irinotecan is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require antidiarrheal therapy. - Nausea and vomiting: typical chemotherapy‑related gastrointestinal upset. - Alopecia: hair loss that is usually reversible. - Fatigue: persistent tiredness affecting daily activities. - Anemia: decreased red blood cell count causing weakness.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe colitis: life‑threatening inflammation of the colon. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

When using Irinotecan, clinicians should observe several safety measures to minimise risks.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: adjust dose in patients with hepatic impairment. Maintain hydration: ensure adequate fluid intake to reduce severity of diarrhea. Avoid strong CYP3A4 inhibitors: concurrent use may increase Irinotecan exposure. Pregnancy: contraindicated unless potential benefit justifies the risk. Store below 25°C: keep in original packaging, protect from moisture.

Irinotecan may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels of Irinotecan. - UGT1A1 inhibitors (e.g., atazanavir): increase exposure to SN‑38, heightening toxicity. - Concurrent myelosuppressive agents: can exacerbate neutropenia and anemia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): require dose adjustment and monitoring. - Anticoagulants (e.g., warfarin): increased bleeding risk due to potential platelet effects. - Antidiarrheal drugs (e.g., loperamide) used at high doses: may mask early signs of severe diarrhea.